Related Experiment Video
Updated: Sep 13, 2025

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Dopamine D2/D3 receptor availability and working memory in stimulant use disorder
Andy C Dean1,2, Daicia Allen1, Megan McClintick1
1Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience, David Geffen School of Medicine, Los Angeles, CA, USA.
Abstract:
Background: Dopaminergic neurochemical markers are associated with working memory performance in healthy participants and patients with schizophrenia. Individuals with stimulant use disorder have below-control levels of dopaminergic markers, such as striatal D2-type receptor (D2/3 R) availability (i.e. D2 + D3 subtypes), and they underperform healthy controls on tests of working memory.Objectives: For consideration in the design of treatments for stimulant use disorder, we tested whether working memory and D2/3 R availability are related in this population.Methods: Eighty-four adults with stimulant use disorder at varying lengths of abstinence (74 with methamphetamine use disorder, 10 with cocaine use disorder; 61/23 male/female) and 47 control subjects (26/21 male/female) completed the Spatial Capacity Delayed Response Task (SCAP), a test of working memory. In the stimulant group only, a subset (n = 52) underwent positron emission tomography (PET) using the D2/3 R ligand [18F] fallypride. Correlation between SCAP performance and D2/3 R availability was tested in bilateral cortical regions of interest previously associated with working memory (frontal, parietal, insular, and cingulate).Results: Controlling for demographics and estimated intelligence, participants in the stimulant group underperformed the control group on the SCAP (F(1, 125) = 5.58, p < .05). In the subset of the stimulant group who received PET, SCAP performance was positively related to D2/3 R availability in the cingulate cortex (β = 0.43, p < .013, Bonferroni corrected).Conclusion: The findings suggest that the weakness in working memory in participants who use stimulants reflects a deficit in cortical D2/3 R signaling. Strategies to augment cortical D2/3 R signaling may enhance cognitive function to improve treatment response.
More Related Videos
07:25Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
Published on: March 27, 2018
05:14Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Drug Abuse and Addiction: Pharmacological Phenomena
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drugs Affecting Neurotransmitter Release or Uptake